TB-500 (thymosin beta-4 fragment): mechanism, evidence, and protocol

TB-500 is the synthetic fragment of thymosin beta-4 (TB4) that has become the companion peptide to BPC-157 in most tissue-repair conversations. Where BPC-157 acts primarily through angiogenesis and fibroblast mobilisation, TB-500 works through a different pathway — actin binding, cell migration, and broad anti-inflammatory modulation. The two peptides are often stacked because their mechanisms are complementary, not redundant.

What TB-500 is#

TB-500 is a synthetic peptide corresponding to a 17-amino-acid active fragment of native thymosin beta-4 (TB4). TB4 itself is a naturally-occurring 43-amino-acid peptide found abundantly in platelets, wound fluid, and many other tissues. It plays roles in actin sequestration, wound healing, and cellular migration across multiple tissue types.

Manufacturers synthesize the shorter TB-500 fragment because it retains the key biological activity of full-length TB4 while being dramatically easier to produce and more stable in solution. For practical purposes TB-500 and "thymosin beta-4 fragment" refer to the same research compound.

TB-500 is administered subcutaneously or intramuscularly. Unlike BPC-157, which shows site-specific effects favouring injection near injury, TB-500's pharmacology appears more systemically uniform — any subcutaneous injection site distributes broadly through tissues.

The mechanism: actin binding and cell migration#

TB-500's primary mechanism is actin sequestration. Actin is the cytoskeletal protein that gives cells their shape and powers their movement. TB-500 binds to monomeric G-actin, regulating the dynamic balance between G-actin and filamentous F-actin that cells need to migrate, divide, and remodel.

The downstream effects:

• Cell migration: immune cells, fibroblasts, and stem cells move more readily to injury sites
• Angiogenesis: endothelial cell migration supports new blood vessel formation, complementing BPC-157's VEGFR2-driven angiogenesis
• Myocyte regeneration: preclinical cardiac models show TB-500 accelerates recovery after ischaemic injury
• Anti-inflammatory modulation: reduces pro-inflammatory cytokine expression, particularly in cardiac and muscle tissue
• Collagen remodelling: supports orderly collagen deposition in healing tissue rather than disorganised scar formation

The mechanism is broader than BPC-157's. BPC-157 targets fibroblast migration and vascular sprouting specifically. TB-500 affects almost every cell type that migrates.

Preclinical evidence#

The preclinical literature on TB-500 and native TB4 is substantial:

• Cardiac tissue repair: multiple studies show improved cardiac function after myocardial infarction in animal models
• Wound healing: accelerated re-epithelialisation and reduced scarring in dermal wound models
• Muscle recovery: faster functional and structural recovery in muscle trauma models
• Tendon and ligament: improved tensile strength and cellular infiltration in healing connective tissue
• Neurological protection: preliminary evidence for reduced stroke damage in rodent models

The quality and breadth of the preclinical work is comparable to BPC-157's. What's missing is the same thing that's missing for BPC-157: large-scale human outcome trials.

Human clinical evidence#

Human TB-500 data is extremely limited. A handful of early-phase trials have been registered, primarily for cardiac and neurological indications, but published Phase 3 outcome data does not yet exist as of April 2026. Most practical use of TB-500 is based on preclinical extrapolation and accumulated research-use experience rather than randomised controlled evidence.

That framing matters for protocol decisions. Anyone choosing TB-500 for a specific outcome should understand they're operating within a preclinical-plus-case-series evidence base, not a clinical-trial-validated one.

Dosing and administration#

Research-use TB-500 protocols converge on a loading-plus-maintenance structure:

• Loading phase: 2–2.5 mg once weekly for 4–6 weeks
• Maintenance phase: 2 mg every 2–4 weeks, or as symptom-driven
• Route: subcutaneous injection, any site
• Typical cycle: 8–12 weeks total for acute injury recovery

Dosing is in mg, not mcg — TB-500 is used in larger amounts than BPC-157. Reconstitution math: a 5 mg TB-500 vial reconstituted with 2 mL of bacteriostatic water gives 2.5 mg/mL. A 2 mg dose equals 0.8 mL = 80 syringe units. A 2.5 mg dose equals exactly 1 mL = 100 units. The Syntho peptide calculator handles any vial size.

Because TB-500 is weekly rather than daily, a single 5 mg vial typically lasts 2–3 weeks on protocol. A 12-week research cycle usually consumes 4–6 vials.

Side effects and safety#

The TB-500 safety profile in preclinical data and research-use experience is benign:

• Injection-site irritation (minor, transient)
• Brief lethargy or fatigue in the 24 hours after dosing
• Occasional mild headache
• No drug interactions of clinical significance have been characterised

No serious adverse events have been reported in any published human pilot work with TB-500 at research doses.

Regulatory status#

TB-500 is not approved as a medicine in the United States, the European Union, or Norway. Legemiddelverket has not authorised TB-500 for any indication. Access in Norway is research-use only through specialised suppliers. Syntho's catalogue stocks TB-500 research product.

TB-500 vs BPC-157#

The two peptides are often conflated, but their mechanisms are distinct:

	BPC-157	TB-500
Amino acids	15	17 (fragment of 43 aa parent)
Primary mechanism	VEGFR2, Akt-eNOS, fibroblast migration	Actin binding, cell migration
Best preclinical evidence for	Tendon, ligament, GI mucosa	Cardiac, skin wounds, muscle, stroke
Dose magnitude	Hundreds of mcg daily	Milligrams weekly
Injection proximity	Prefer near injury	Any site
Typical cycle length	4–8 weeks daily	8–12 weeks weekly

The reason protocols often stack them is that their mechanisms are complementary. BPC-157 promotes local angiogenesis and fibroblast recruitment; TB-500 supports broader cell migration and tissue remodelling. For the stack discussion, see BPC-157 + TB-500 stack. For the individual comparison, see BPC-157 vs TB-500.

Practical summary#

TB-500 is a systemic tissue-repair peptide with strong preclinical breadth and limited human clinical evidence. Its actin-binding mechanism complements BPC-157 rather than duplicating it. Research-use protocols typically run a 4–6 week loading phase at 2–2.5 mg weekly, followed by reduced-frequency maintenance.

For anyone considering TB-500:

• Syntho's questionnaire handles the screening
• The peptide calculator handles the reconstitution math
• The titration calculator builds week-by-week schedules
• The reconstitution guide covers the mechanics

TB-500's case is not weaker than BPC-157's. It's just different: broader mechanism, more systemic, less site-specific. That makes it a useful peptide to have in the research-protocol toolkit, not a drop-in substitute.